ProShare Advisors
ORIC icon

ProShare Advisors’s Oric Pharmaceuticals ORIC Stock Holding History

ProShare Advisors’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$143K Sell
13,178
-901
-6% -$8.17K ﹤0.01% 1725
2026
Q1 		$178K Sell
14,079
-2,313
-14% -$26.3K ﹤0.01% 1617
2025
Q4 		$134K Buy
16,392
+3,009
+22% +$34.6K ﹤0.01% 1816
2025
Q3 		$161K Buy
13,383
+1,527
+13% +$16.1K ﹤0.01% 1751
2025
Q2 		$120K Sell
11,856
-4,675
-28% -$31.4K ﹤0.01% 1841
2025
Q1 		$92.2K Sell
16,531
-4,152
-20% -$36.3K ﹤0.01% 1850
2024
Q4 		$167K Buy
20,683
+4,881
+31% +$44.8K ﹤0.01% 1940
2024
Q3 		$162K Buy
+15,802
New +$156K ﹤0.01% 1783
2024
Q2 		– Sell
-11,733
Closed -$161K – 1957
2024
Q1 		$161K Buy
+11,733
New +$139K ﹤0.01% 1725
2022
Q1 		– Sell
-12,447
Closed -$184K – 2273
2021
Q4 		$184K Sell
12,447
-2
-0% -$31 ﹤0.01% 2065
2021
Q3 		$260K Sell
12,449
-1,869
-13% -$37.9K ﹤0.01% 1647
2021
Q2 		$253K Buy
14,318
+3,187
+29% +$69.8K ﹤0.01% 2000
2021
Q1 		$273K Buy
11,131
+562
+5% +$17.8K ﹤0.01% 1858
2020
Q4 		$358K Buy
+10,569
New +$303K ﹤0.01% 1494

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ProShare Advisors's ORIC Position: Q2 2026 in Review

ProShare Advisors reduced its Oric Pharmaceuticals (ORIC) stake by 6.4% in Q2 2026, selling an estimated $8.17K and leaving 13,178 shares worth $143K. The position accounts for ﹤0.01% of the portfolio, ranked #1725.

ProShare Advisors first reported a position in ORIC in Q4 2020 and has held it in 14 quarters since. The position peaked at $358K in Q4 2020. 181 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • ProShare Advisors held 13,178 shares of Oric Pharmaceuticals worth $143K as of Q2 2026.
  • ProShare Advisors sold 901 Oric Pharmaceuticals shares in Q2 2026, an estimated $8.17K.
  • Oric Pharmaceuticals made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1725 holding.
  • ProShare Advisors first reported a position in Oric Pharmaceuticals in Q4 2020 and has held it in 14 quarters since.
  • ProShare Advisors's Oric Pharmaceuticals position peaked at $358K in Q4 2020.
  • 181 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.